Tracking colorectal cancer response using blood tests
Part of Cancer, Digestive system clinical trials.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer (cancer that has spread beyond the colon or rectum) that cannot be surgically removed
- Your cancer has been confirmed by biopsy or tissue sample
- You have at least one measurable tumor (at least 10mm) visible on CT or MRI scan done within 28 days of starting the trial
- You are starting chemotherapy for the first time for metastatic disease
- You are in good enough health to tolerate treatment (normal blood work, kidney, liver, and clotting function)
- You have no cancer in your brain and no other active cancers (except skin cancer or past cancers treated more than 3 years ago)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adjusting treatment based on a simple blood test (circulating tumor DNA) after two cycles of chemo can be safe and effective for people with advanced colorectal cancer. The goal is to tailor therapy to each person's response.
This study looks at a simple blood test to track colorectal cancer that has spread. It may allow doctors to monitor the cancer without needing repeated scans or biopsies, helping them adjust treatment more accurately.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This study tests if a simple blood test can help watch for cancer returning after surgery in people with colorectal cancer that has spread to other organs. It aims to improve follow-up care and help you feel more in control of your treatment.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
This study looks for early signs of colorectal cancer and ways to check if it comes back after treatment. It uses blood samples to find markers that could help doctors diagnose and monitor the disease more effectively.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.